Company news
Tempramed Technologies Ltd. (CSE:VIVI) news
Tempramed Technologies Ltd. news releases on 6ix. Latest, Oct 5, 2026: TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit…
Press releases & updates
TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking
October 5, 2026
TempraMed Technologies Ltd. Announces Closing of Private Placement
September 30, 2026
TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
September 29, 2026
TempraMed Announces Upsize to Offering
September 28, 2026
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
September 24, 2026
TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
September 23, 2026
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
September 18, 2026
TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece
September 1, 2026
TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap
August 25, 2026
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
August 20, 2026
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
August 18, 2026
TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness
August 4, 2026
TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
July 30, 2026
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
July 9, 2026
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
July 6, 2026
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
June 30, 2026
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
June 26, 2026
TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally
June 4, 2026
TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications
May 22, 2026
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
May 14, 2026
TempraMed Announces Continuance into Ontario
April 29, 2026
TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product
April 7, 2026
TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure
March 30, 2026
TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box
March 24, 2026
TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap
March 11, 2026
TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States
February 26, 2026
TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy
February 10, 2026
TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel
February 6, 2026
TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
February 2, 2026
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
January 23, 2026
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
January 14, 2026
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement
January 12, 2026
TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
January 6, 2026
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
January 2, 2026
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
December 31, 2025
TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
December 26, 2025
TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
December 17, 2025
TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
December 15, 2025
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
December 10, 2025
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
December 8, 2025
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
December 5, 2025
TempraMed Technologies Ltd. (CNSX:VIVI) Exclusive Commercial Distribution Agreement with Turkish Medical Device Supplier
December 3, 2025
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
December 2, 2025
TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
November 26, 2025
TempraMed Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
November 18, 2025
TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon
October 27, 2025
TempraMed Announces Private Placement of up to C$2.5 Million
October 21, 2025
Canadian Securities Exchange Welcomes Listing of TempraMed Technologies Ltd.
October 15, 2025